A Phase I randomised, open-label, two-period crossover study of CK 2127107 in healthy male volunteers

Trial Profile

A Phase I randomised, open-label, two-period crossover study of CK 2127107 in healthy male volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 13 Oct 2014

At a glance

  • Drugs CK 2127107 (Primary)
  • Indications Muscular atrophy
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Astellas Pharma
  • Most Recent Events

    • 13 Oct 2014 Status changed from recruiting to completed, according to a Cytokinetics media release.
    • 13 Oct 2014 Results published in the Media Release.
    • 18 Mar 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top